Search Results - Mark A. Ator

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Protein control of prosthetic heme reactivity. Reaction of substrates with the heme edge of horseradish peroxidase.

    Protein control of prosthetic heme reactivity. Reaction of substrates with the heme edge of horseradish peroxidase. by Mark A. Ator, P.R. Ortiz de Montellano

    Published 1987
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

    A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis by Kristine L. Stump, Lily Lu, Paweł Dobrzański, Cynthia Serdikoff, Diane E. Gingrich, Benjamin J. Dugan, Thelma S. Angeles, Mark S. Albom, Mark A. Ator, Bruce D. Dorsey, Bruce Ruggeri, Matthew M. Seavey

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

    Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2 by Lily Lu, Kristine L. Stump, Nate H. Wallace, Paweł Dobrzański, Cynthia Serdikoff, Diane E. Gingrich, Benjamin J. Dugan, Thelma S. Angeles, Mark S. Albom, Jennifer Mason, Mark A. Ator, Bruce D. Dorsey, Bruce Ruggeri, Matthew M. Seavey

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers

    CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers by Mangeng Cheng, Matthew R. Quail, Diane E. Gingrich, Gregory R. Ott, Lihui Lü, Weihua Wan, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, Flavio Cristofani, Rodolfo Machiorlatti, Cristina Abele, Mark A. Ator, Bruce D. Dorsey, Giorgio Inghirami, Bruce Ruggeri

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

    Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor by Joel Kaye, Victor Piryatinsky, Tal Birnberg, Tal Hingaly, Emanuel Raymond, Rina Kashi, Einat Amit‐Romach, Ignacio Caballero, Fadi Towfic, Mark A. Ator, Efrat Rubinstein, Daphna Laifenfeld, Aric Orbach, Doron Shinar, Yael Marantz, Iris Grossman, Volker Knappertz, Michael R. Hayden, Ralph Laufer

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer

    Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer by Weiguo Xiang, Lijie Zhao, Xin Han, Tianfeng Xu, Steven Kregel, Mi Wang, Bukeyan Miao, Chong Qin, Mingliang Wang, Donna McEachern, Jianfeng Lü, Longchuan Bai, Chao‐Yie Yang, Paul D. Kirchhoff, John Takyi‐Williams, Lu Wang, Bo Wen, Duxin Sun, Mark A. Ator, Robert McKean, Arul M. Chinnaiyan, Shaomeng Wang

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment

    Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment by Amar Mirza, Micah A. Fry, N. Urman, Scott X. Atwood, Jon Roffey, Gregory R. Ott, Bin Chen, Alex Lee, Alexander S. Brown, Sumaira Z. Aasi, Tyler Hollmig, Mark A. Ator, Bruce D. Dorsey, Bruce Ruggeri, Craig A. Zificsak, Marina Sirota, Jean Y. Tang, Atul J. Butte, Ervin H. Epstein, Kavita Y. Sarin, Anthony E. Oro

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and <i>In Vivo</i> Antitumor Activity

    CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and <i>In Vivo</i> Antitumor Activity by Joyce James, Bruce Ruggeri, Robert C. Armstrong, Martin W. Rowbottom, Susan Jones‐Bolin, Ruwanthi N. Gunawardane, Paweł Dobrzański, Michael F. Gardner, Hugh Zhao, Merryl Cramer, Kathryn Hunter, Ronald R. Nepomuceno, Mangeng Cheng, Dana Gitnick, Mehran Yazdanian, Darren E. Insko, Mark A. Ator, Julius Apuy, Raffaella Faraoni, Bruce D. Dorsey, Michael Williams, Shripad S. Bhagwat, Mark W. Holladay

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: